ContactIGES Pharma UK
Local Insight. Global Impact.
Navigating the UK Market Access environment can be complex and dynamic and requires local home-grown expertise to ensure timely access for around 70 million patients across the UK.
85% of submissions face challenges without expert advice with an average of 12-18 months for a NICE technology appraisal.
To navigate the system, there are 6 key areas for consideration with 6 key stakeholder groups to consider and at IGES UK Pharma we offer 6 key areas of expertise to match considerations.
Areas of consideration
Early engagement with key stakeholders, evidence gap analysis, and development of value proposition aligned with UK healthcare priorities.
Navigating MHRA approval process, ensuring compliance with UK regulations post-Brexit, and managing the licensing pathway.
Preparation and submission to NICE, SMC, or AWMSG, including economic modeling, clinical evidence synthesis, and committee engagement.
Negotiation with the Department of Health and Social Care, development of Patient Access Schemes, and agreement on pricing.
Implementation support, formulary inclusion strategies, and addressing local commissioning barriers to ensure patient access.
Real-world evidence generation, outcomes monitoring, and lifecycle management to maintain market position.
Key Access Stakeholders
National Institute for Health and Care Excellence - Provides national guidance and advice to improve health and social care.
Department of Health and Social Care - Responsible for government policy on health and adult social care matters.
Local Integrated Care systems oversees the budget, planning, delivery and day to day operation of the commissioning side of the NHS in England with similar bodies in Wales and Scotland.
Medicines and Healthcare products Regulatory Agency - Regulates medicines, medical devices and blood components.
Scottish Medicines Consortium and All Wales Medicines Strategy Group - Provide advice on new medicines to NHS Scotland and Wales.
Influential organizations representing patient perspectives in health technology assessment decisions.
Areas of expertise - Our Services
Development of integrated market access strategies aligned with UK healthcare priorities and payer evidence requirements.
End-to-end support for NICE, SMC, and AWMSG submissions including dossier development, economic modelling, and committee representation.
Strategic pricing analysis, development of Patient Access Schemes, and negotiation with DHSC for optimal reimbursement.
KOL mapping, engagement planning, and advisory boards with NHS decision-makers, clinicians, and patient groups.
Real-world evidence studies, systematic literature reviews, and value dossier development tailored to UK requirements.
Continuous tracking of UK pharmaceutical policy developments, NHS reforms, and implications for market access.
Why IGES Pharma
- Integrated Support: From strategy to execution, we offer seamless guidance through every phase of your product’s journey with over 35 Years of experience in the UK System.
- Tailored Approach: We adapt our frameworks to your specific product, disease area, and company needs aligned with not only the changing environment but also to the future UK policy plans and adaptations.
- Global Alignment with Local Focus As part of IGES Pharma Group, we ensure your strategy is locally tailored and globally aligned.
